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ABSTRACT Both culturally and biologically, India is one of the mega diversity countries of the world. This pertains
to Human Genome Diversity as well. Although little explored so far, HLA is no exception to this. HLA profile varies
based on regional, linguistic and caste profiles. HLA alleles identified as common in HIV non progressors in other parts
of the world are the commonest in the Vellala related communities of southern India. Migration and selection might
be responsible for this.  In the context of the well established MHC restriction phenomenon and the role of CTL in
controlling HIV viral replication, it has become essential to revisit these areas and better understand the underlying
phenomena so that better experiments are designed in future research. The article highlights these aspects in the
context of HIV pandemic in India.
INTRODUCTION
India is one of the megadiversity countries
of the world with unique fauna and flora. Similarly
India is also a mega diversity country in terms of
Human species as well. This can be attributed to
the early settlement of Man in India, since ~
50,000 years, through coastal (southern route)
and land routes. From hunter gatherer he started
leading a settled life as a result of ‘social’ hunting
and organized agriculture.  Man thus settled in
more ideal ecological niches such as Merghargh
of present day Afghanistan, Swat Pirak culture
in northern India, IndoGangetic doab riverine
culture and Kaveri Delta and Athichanallur in
Tamil Nadu  (Kochhar 2000; Wells et al. 2001).
The ecological factors such as climate, rainfall
temperature and monsoon (seasonal cycles) were
then ideal for human survival in India. Hence
having settled in a particular place He expanded
in population size, learnt better water manage-
ment and irrigation techniques which transformed
Him into a social creature. These populations in
earlier settlements must have been subjected to
the prevailing or brought in infectious agents
such as virus and bacteria that might have acted
as bottle necks and/or selection pressures in
terms of immunology. Two factors thus might
have effectively contributed to the shaping of
the genomic diversity of the Major Histocompati-
bility (MHC) system more particularly the Human
Leucocyte Antigen system A (HLA): i) place of
origin and/or migration and ii) the prevailing
infectious diseases enroute to and in the place
of settlement. This probably resulted in the
prevailing scenario of HLA distribution in India
and the world.
In this article, we describe the genomic
diversity of the most important immunogenetic
system of our body, viz. HLA that is responsible
for the recognition of self from non-self and most
importantly in protecting all of us from particular
infections. We present here the basic premise on
which the immunogenetics has been built on the
past four decades. It is the most extensively
studied genetic polymorphisms of our system.
Any clinical or population based study as on
date invoking a immunological/genetic basis for
a disease or disorder needs to essentially
consider the host gene pool particularly the HLA/
MHC for drawing better conclusions.
I.  MHC  AND  HLA
Major histocompatibility complex is present
in all the Chordates studied so far, with the
increasing order of complexity of structure,
function and polymorphism through vertebrate
evolution (HLA is a part of the major histo-
compatibility system of humans).
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Discovery of MHC: Genetic basis of immune
responses have now been amply confirmed. The
pioneering work of Jean Dausset describing the
white cell agglutinins during the Second World
War has lead to the discovery of the MHC system.
The recognition for this was the Nobel Prize in
Physiology and Medicine awarded to him in 1980,
jointly with George D. Snell, discoverer of the
Mouse strains, and Baruj Benaceraaf for his Ir
gene complementation. Having received the Nobel
Prize although many were in queue to fund his
research the earliest research grant of this great
scientist was from Lady Tata Trust (personal
conversation with RMP in 1981).
Rolf Zinkernagel and Peter Doherty  described
the MHC restriction phenomenon in 70’s the first
evidence for a probable role of MHC that turned
out to be true till today, for which they received
the Nobel Prize in the year 1996. This seminal
discovery led to the newer understanding of the
immune system and functions, biophysical basis
of peptide binding and thymic education,
explaining the molecular  basis of generation of
diversity in immune repertoire (cf Roitt et al. 2006).
X-ray crystallography and better understanding
of the structure of the MHC molecules and its
peptide binding grooves provided the convinc-
ing evidence for the bio-physical basis of the
trigger that initiates an immune response
(Madden et al. 1989).
Of late, the HIV/AIDS pandemic and the
search for its HLA association have brought out
the direct clinical evidence of this MHC restric-
tion phenomenon in Cytotoxic T Lymphocyte
(CTL) generation and its role in disease control.
MHC Genetics: Major Histocompatibility
Complex encompasses a region of 3500 kb, in the
short arm of chromosome 6 p21.3. There are 220
loci and majority of them are involved in immune
response (Bhattacharya et al. 2007). Two of these
clusters called Klein class I and Klein class II
originated by gene duplications and each one of
them consists of a handful of closely (functionally
and structurally) related loci (Table 1). Klein
performed his studies in 1988 and Klein Class I
and II are more popularly known as HLA class I
and II loci. Classical examples of Klein class I are
HLA-A, B and C loci and that of Class II are
HLA-DR, DP and DQ, earlier all defined
serologically by employing Human allo-antisera.
These alleles are inherited in a Mendelian fashion
and are co-dominant. With the advent of DNA
technologies, the alleles are defined at sequence
level. The allelic polymorphism is the highest in
HLA B locus (894 alleles) and HLA DRB1 locus
(577 alleles) as on May 2007 (Table 1). Klein class
I alleles codes for the heavy chain of the
molecules and a dimer formed with beta 2 micro-
globulin are expressed on all the cells and tissues
of our body (‘Identity Card’, called Tissue or
Transplantation antigens). Klein class II
expression is specific to the cells of the immune
system and further their expression is restricted
to B lymphocytes and activated T cells of the
immune system.
The serological specificities of yesteryears
are designated as HLA-A2, HLA-B57, HLA-DR15
etc. Their exact alleles defined at the sequence
level are designated as HLA-A*0201, HLA-
B*5701 and HLA-DRB1*150101, respectively.
Each serological specificity, identified by an
antiserum, is now described at the exact sequence
level and is comprised of many alleles. For
example, HLA-B35 has 85 alleles as on date,
which are characterized by exact sequence
differences in the alpha helixes and Beta sheet of
peptide binding groove of HLA molecule.
MHC Peptide Binding Groove: The peptide
binding grooves of these HLA molecules hold
the key for the specificity of recognition in the
immune system. Only if there is a good fit of this
peptide binding groove with that of the MHC-
peptide complex (neoantigen hypothesis), the
peptide will be presented and antigen recognition
Table 1: Major HLA Loci, their Alleles and Proteins
involved in antigen presentation and immune
responses, May 2007
(cf: IMGT/HLA data base, http://www.ebi.ac.uk/imgt/hla/
stats.html
Numbers of HLA Alleles
HLA Class I Alleles 1,839
HLA Class II Alleles 875
HLA Alleles 2,714
Other non-HLA Alleles 102
HLA Class I
Gene A B C
Alleles 545 894 307
Proteins 436 766 244
Nulls 39 31 7
HLA Class II
Gene DRB DQB1 DPB1
Alleles 577 83 126
Proteins 476 61 113
Nulls 7 1 2
HLA Class II - DRB Alleles
Gene DRB1
Alleles 494
Proteins 418
Nulls 2
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by the T cell will take place. Class I molecules
bind peptides of 9 amino acid length and class II,
9-12 amino acid long ones. Furthermore, not all
amino acids are important, only specific pockets
of the peptide binding groove and given residues
of the peptide are important in this binding and
these are called ‘Consensus Motifs’ (cf. Roitt et
al. 2006). There is no guarantee that all the
peptides generated by Antigen Presenting Cells
(APC) of an individual will bind and be presented
by all the HLA molecules and only those with
good fit (consensus motifs) will be presented
and may be recognized by T cells, thus providing
scope for  the enormous amount of diversity and
immune response that can be created in the
process.
II.  HLA  IN  THE  POPULATIONS  OF  INDIA
Allelic Polymorphisms: Table 2-3 presents
the phenotype frequencies (at the serological
level) of various populations from southern India
studied in our laboratory (www.geocities.com/
rdbgy; Pitchappan 2002). The Indian populations
have not been extensively studied for HLA
polymorphisms and there are only a few sporadic
literatures on exact allele frequencies as on date.
Table 4-5 presents the HLA DRB1, HLA-A, B
allelic and selected haplotype frequencies
reported in various Indian studies . A few
important observations can be made from this
table: i) a gradient of an allele frequency from
east to west,  ii) higher frequency of a given allele/
haplotype in a geographical region/ caste and iii)
one daughter allele of a given parent allele
occurring in one geographical region while the
other in another geographical region. For
example, HLA-DRB1*16, one split (daughter
allele) of HLA DR2 specificity  being prevalent in
Eastern Europe while the other split, (HLA
DRB1*15) is common in India and its east.
Similarly HLA-DRB1*11 and *12, splits of DR5,
and DRB1*13 and DRB1*14, splits of DR6 are
prevalent in two different geographical areas
(Shanmugalakshmi et al 2003). Simplest
explanation for this kind of pattern of two
different daughter alleles of a parent allele seen
in two different geographical locations/ isolates
could be the common origin of the daughter
alleles in the ancient settlement and their
subsequent dispersal in two different directions
due to migration.  The picture is more clear with
DRB1* and Haplotypes (Table 6). The picture
with HLA A and B alleles in Indian populations
are the tip of the iceberg, though these estimates
suffer because of low sample numbers in many
studies. Thus one cannot be sure of the
contributions by migration and bottle neck effects
leading to the present scenario: one may have to
examine these issues in the context of other
genomic diversities, with better study designs
and sample size.
HLA Profile of Indian Population and
Its Implications
From our studies of HLA and from those
available in literature, we found differences
between  different regions and populations of
India (Pitchappan et al. 1997; cf. Shanmugalakshmi
et al. 2003) as many report (Gosh 2007). Each
south Indian caste group studied has their own
HLA profile and ‘more related’ caste groups have
more similar profiles (Pitchappan et al. 1988). This
picture has been correlated to many diseases and
immunological phenomena as indicated in the
publications from our laboratory (Pitchappan et
al. 1988, 1989, 2002).  This can be further exempli-
fied by correlating this profile to their migratory
backgrounds  and genetic epidemiology.
An ancient isolated population Piramalai
Kallars numbering about 0.3 million, living in two
provinces (taluks) west of Madurai have the
highest frequency of high risk allele for TB, HLA-
DRB1*1501; almost every alternate individual of
this  population possesses HLA DRB1 *1501 but
TB was not common among them, probably for
want of close contacts and the resultant trans-
mission from the affected individuals and due to
the lack of conducive environment for mani-
festing the disease (Pitchappan et al., unpublish-
ed results). The villages  are situated in highly
arid, healthy atmosphere amidst paddy fields with
lot of fresh air. Every alternate individual from
this caste also possesses M20 NRY chromosome
marker (Wells et al. 2001). This marker presumably
originated 30,000 years ago in  India representing
one of the earlier migrations into India (www.
nationalgeographic.com/genographic). Thus
whether the higher frequency of DRB1*1501 and
M20 are due to founder effect, bottle neck or
selection need to be further explored.
Sourashtrians of Madurai who are thought
to have originated in Eurasian Steppes represent-
ing Indo Iranian nomadic culture, and responsible
for Indo-European languages  possess NRY-M17
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HLA B Allele
Parsis
Marathas
Bhils
Pawar
Golla
Adiya
Paniya
Kanikkar
Kurumba
Kurichiya
Ezhavas
Pulaya
Malapanadram
Random non-tribal
Dravidian group
Nair
Syrian Christian
Malabar Muslim
Namboothiri
Kattunaikka
Irula
Nadar
Kallars*
Nadar*
Iyer
Sourashtra
Malayali*
Naidu*
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The maximum observed frequency of a given allele and that are >50% of this, are highlighted. DR5, DR6, DR2 are the
serological specificites, obtained adding the split alleles (with brackets)
References cited: a - Suciu-Foca et al. 1981;  b - Carrington et al. 2002; c - “<http://www.allelefrequencies.net>”;
d - Pitchappan et al. 1997;  e - Balakrishnan et al. 1996;  f - Ravikumar et al. 1999;  g - Shanmugalakshmi et al. 2003.
Other legends as per table 2
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and this allele is the commonest in Central Asia
and common in northern parts of India as well.
Many of the Indian populations possess HLA-
B17 and HLA A1-B17 haplotypes (Table 5): this
allele and haplotype were the commonest in India
and called as “Telugu haplotype” by Hammond
in Indians settled at Durban, South Africa
(Hammond et al. 1979).  This allele is distributed
through out India at a lower but consistant
frequency of 0.05 to 0.1. The difference in the
HLA frequencies and NRY of the two populations
mentioned above suggest the possibility of
different origin of these populations, their
expansion in varied ancient settlements and
probable differential susceptibility to infection
in these settlements. Molecular epidemiology
may throw further light on these aspects.
III.  IMPLICATIONS
Recognition of MHC Peptide Complex: The
Zinkernagel and Doherty phenomenon mention-
ed earlier revolves around the MHC (HLA)-
Table 4: HLA DRB1* Allele frequencies (x100)  of selected southern Indian populations (castes & tribes)
peptide binding: a CTL generated in response to
a given MHC-peptide complex knows to kill the
homologous MHC peptide complex bearing cells
only i.e., the cells of the same host genetic H2
(similar to HLA in mouse) make up, infected by
the same virus. The CTL generated under one
MHC background does not know to identify any
other antigens or MHC background (Doherty
1997)
This is what exactly happens in every viral
infection including HIV infection. Nature has
invented CTL to kill only the homologous virus
infected cells in our body and not other uninfected
cells and tissues in the vicinity or any other virus/
epitope (the 9 or 12 amino acid antigen deter-
minant generated by the APC, bound and
presented by the MHC and recognized by the T
cell/ B cell of the immune system).
HLA, CTL and Long Term Non Progressors:
The importance of CTL in keeping at bay the HIV
infection has been shown in many HLA
association studies. Table 6 provides a list of
recent studies wherein the HLA is reported to be
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Table 6: Selected Literatures on HLA B association in HIV pathogenesis
Reference Population Risk Alleles Protective allele              Effect
Lazaryan et al 2006 Zambians, HLA-B58 B*5703, Viral load lower in B*5703
Rwandans Supertype B*5703-Cw*18 but not in B-58
Bailey et al 2006 USA HLA-B*57 Low plasma viral load
(<50 copies / ml)
Stewart-Jones et al 2005 UK HLA-B*5701 or Long Term Non Progression;
HLA-B*5703. crystal structure
Frahm et al 2005 USA HLA-B*63 Presents B-57 binding epitopes,
low viral load (3,280 RNA copies/ml)
Munkanta et al 2005 Japan HLA-B*5401 HLA-B*1507
Gaudieri et al 2005 Australia HLA-B*5701,
HLA-B*2705 Protection against viraemia
Papasteriades et al 2005 Greece HLA-A28, B21 Fast progressors
and DR3,
Brown et al 2005 USA HLA-A2 27-kD Nef protein down-modulate
Lopez-Vazquez et al 2005 Zambia B57 Protection
Stephens 2005 Caucasoid, B57, B58 low viraemia, delayed onset of AIDS
African
Tomiyama et al 2005 Japan HLA-B*5101 slow progression to AIDS
den Uyl et al 2004 HLA-B27 strong CTL response against
the p24 epitope
Kiepiela et al 2004 South Africa HLA-B57, B58 Low viral load,
Altfeld et al 2003 HLA-B57 Low viral load
.
Table 5: Contd.....
Reference t q q q q q q q q q q q k
Language ST ST ST ST ST ST ST ST ST ST ST ST ST
State
Sample size$ 112 68 138 160 126 85 266 86 407 403 315 472
A1-B8
A10(26)-B8 39 54
A2-B40 6 12 12
A1-B17 55 19 15 19 24
A3-B7 10
A33-B44 97 55 36 7 9 68 41 341
A1-B37 68 5 15 5
B37-DR10
B57-DR7 16
A2-B46 68 133 64 106 43
A33-B17 46 39 35
A33-B58 47 46 59 115 133
B58-DR3 38 58 55
A2-B44 18 38 31
A24-B7 27 57
A26-B61 18 31
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associated with HIV infection and progression.
While there was no unanimity of the identified
associations in the yesteryears, many studies
now have shown a correlation between HLA-
B*57, 27, 15, and 51 with protection mediated by
strong CTL responses, low viraemia, and delayed
onset and slow progression towards AIDS.  A
few other alleles such as A2, A28, B21, DR3 and
DR5 are high risk alleles for HIV susceptibility. It
is essential that an active CTL repertoire is
maintained to check the disease under control,
with low viral load and non progression towards
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AIDS. Sometimes escape mutants also arise under
certain MHC background (Leslie et al. 2004).
Another study employing HIV viral overlap
peptides and CTL responses has shown a
dominant effect of HLA-B restricted CTL
responses (Kiepiela et al. 2004). The mechanism
of HIV susceptibility and progression thus
includes (i) HLA B locus alleles associated with
peptide specific responses, (ii) plasma viraemia
and CD4 counts varying according to the HLA-
B allelic polymorphism, (iii) HLA B alleles
associated in general with non-progression
compared to other HLA loci and (iv) HLA B allele
homozygosity disadvantage reflecting in the
severity of infection.
All these results need to be viewed in the
context of the host genomic diversity of the
involved genes, such as alleles of various HLA
loci and also the diversity at the level of viral
clades and its dynamics resulting from the strong
immune attack mounted by the host. This
molecular-genetic epidemiology of the host
genetics, parasite diversity, host immune
response and occurrence of viral variants at the
population level looks too intricate (Bhattacharya
et al. 2007), but not impossible to study. Recent
studies on KIR polymorphisms operating at the
level of innate immunity have thrown more light
on the possible effect of such genomic diversity
in the selection processes (Norman et al 2007).
HLA, HIV and Viral Diversity: As mentioned
earlier, many of the HLA alleles implicated in the
HIV pathogenesis and CTL responses are the
commonest in India. For example, the protective
allele HLA B57 is one of the most common in
India and is present in higher frequencies in
Indian populations (Kiepiela et al. 2004). Similarly
B35, A11, DR5 are also quite common. Further
the frequencies of various HLA alleles are also
quite different in various parts of India and in
various linguistic and caste groups (Pitchapan
2002). In southern India, we have observed that
HLA-B*17 HIV seropositives possessed
significantly higher CD4 count compared to
patients carrying other HLA B locus alleles and
HLA A* or DRB1* loci were not  involved in this
association (Pitchappan et al. unpublished
results). The infecting organism in majority of
the patients in India belongs to Clade C and the
virus infecting HLA B57 host is known to develop
‘escape mutants’ by changing the amino acid in
TW10 epitope of Gag protein, thus blunting the
onslaught of CTL mediated killing of infected
cells (Leslie et al. 2004). However, the virus mutates
back to original epitope moiety when transmitted
to a new non-B57 host. If an escape variant reaches
fixation in the population, the epitope will be lost
as a potential target to the immune system, thus
explaining how HIV is evolving at a population
level. Understanding the direction of HIV evolution
thus has important implications for vaccine
development (Bhattacharya et al. 2007; Leslie et
al. 2005).
Considering the enormous number of known
HLA B alleles (N=751) and those new variants
hitherto unknown in India, it may be an intelligent
guess to imagine the diversity created and added
to the population, as a function of time. The
mutations fixed in the escape mutants described
above thus add up to viral diversity in circulation.
In a couple of years, the HLA B alleles that are
protective against HIV may increase in the
population.  Alternatively, many “ineffective”
circulating viruses/clades themselves may also
lead to a status of ‘herd immunity’. The infected
Commercial/Casual Sex Workers (CSW) with HLA
B57 in India may be a good reservoir spreading
the disease, though with low viral load and without
developing a clinical disease or even becoming
seropositive by themselves. From public health
point of view, case finding and targeted anti-
retroviral therapy (ART) or microbicide treatment
of HLA-B57 and related high risk allele carrying,
and non-progressing CSW might be one way of
reducing the load and reservoir of HIV virus in
circulation. Any new generation vaccine
contemplated should induce a sterilizing immunity
in this group of people; else the virus infecting
non-B57 will revert back with sufficient virulence
and the pandemic may continue for long.
The statistics on HIV prevalence in India makes
the policy makers to worry of their responsibilities.
According to 2004 sentinel survey, estimated
prevalence of infection is 5.134 million, but not all
the states are equally bearing the brunt. The
highest prevalence is in Mumbai and Tamil Nadu:
44.7% among the female CSW and 9.6% in MSM
(Men who have Sex with Men) of Mumbai, 39.9%
among IVDU (Intra Venous Drug Users) in
TamilNadu and 15.65% STD clinics of Mumbai
(NACO 2006). It is essential to consider the disease
with the prevailing genetic epidemiological
background, rather than considering it in isolation.
R. M. PITCHAPPAN, V. J. KAVITHA AND M. JAYALAKSHMI152
IV.  FUTURE  DIRECTION
 In India, a multifaceted, multicentric, large
scale study to understand its Immuno-genetic-
epidemiological profile and molecular-
epidemiology of HIV infections, various diseases
and disorders is the need of the hour. A
partnership between various laboratories with
requisite expertise may be highly advantageous,
though less happen than done; though the world
goes the same way! The expertise and knowledge
available in the country and in one country may
thus need to be respected, acknowledged and
harnessed to work in tandem with the meager
resources available globally. The great and long
“Indian Heritage” that has resulted in such a
fascinating sympatricaly isolated gene pools, may
need to be better employed to understand the
differential disease susceptibility.  We might have
answers to most of the diseases in India!
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